Study: Combined Therapies for Cardiac Arrest Give Better Neurological Outcomes

A new study in the July 17 issue of the Journal of the American Medical Association shows improved neurological results in in-hospital cardiac arrest patients requiring vasodepressors on whom a vasopressin-ephinepherine-steroid combination therapy is used.

Advertisement

 
The study included two years of data from 268 patients across three hospitals in Greece. Patients received epinephrine and either vasopressin or a placebo during CPR. Patients who received vasopressin had an 83.9 percent probability of returning to spontaneous circulation compared to the 65.9 percent probability of returning to spontaneous circulation of the other group. 
 

 
In addition, 13.1 percent of patients who received vasopressin were alive and had a favorable neurological recovery compared to just 5.1 percent of patients in the control group. 
 

More Articles on Quality: 

6 Steps to Lower Heart Failure Readmissions

Reducing Preventable Birth Injuries Through Evidence-Based Care, Enhanced Teamwork

Infographic: Communication Gaps From Outdated Technology Pose Threats, Costs

 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

When nurses help build the AI, adoption follows: Lessons from 3 health systems

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Amy McCarthy, DNP, RNC-MNN, NE-BC, CENP, Hippocratic AIBeth Reimschissel, PhD, RN, CNL, Memorial HermannAllison Schlinkert, MSN, RN, NPD-BC, Cincinnati Children'sScott Estep, MBOE, BSN, RN, CSSBB, OhioHealth System

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.